Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy

ConclusionsOur results indicate the potential for the use of sBCMA as a new biomarker for monitoring patients with RRMM.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research